Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.

Publication/Presentation Date

5-5-2018

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a novel and innovative immunotherapy. CAR-T cells are genetically engineered T cells, carrying MHC independent specific antigen receptor and co-stimulatory molecule which can activate an immune response to a cancer specific antigen. This therapy showed great results in hematological malignancies but were unable to prove their worth in solid tumors. Likely reasons for their failure are lack of antigens, poor trafficking, and hostile tumor microenvironment. Excessive amount of research is going on to improve the efficacy of CAR T cell therapy in solid tumors. In this article, we will discuss the challenges faced in improving the outcome of CAR T cell therapy in solid tumors and various strategies adopted to curb them.

Volume

35

Issue

6

First Page

87

Last Page

87

ISSN

1559-131X

Disciplines

Medicine and Health Sciences

PubMedID

29730801

Department(s)

Department of Obstetrics and Gynecology

Document Type

Article

Share

COinS